Fairooz Kabbinavar, MD, FACP

Global Head Research & Development

Dr. Kabbinavar has extensive oncology drug development expertise in the pharmaceutical industry with strong scientific, strategic, operational and leadership skills. With over 25 years clinical and academic experience, he has served in leadership positions at the University of California at Los Angeles (UCLA), Genentech, Tocagen, and Puma Biotechnology. At UCLA, Dr. Kabbinavar held academic appointments as Professor of Medicine and Urologic Oncology, was awarded an Endowed Chair in Cancer Research, served as Director of the medical oncology programs in genitourinary cancers, lung cancer, head and neck cancer and co-director of the brain tumor program, and Chairman of the IRB at Jonsson Comprehensive Cancer Center. His work at UCLA culminated in the approval of Avastin® for treatment of mCRC and at Genentech, his phase III trial in small cell lung cancer resulted in approval of Tecentriq® for ES-SCLC. Dr. Kabbinavar received his MD from Nagpur University and completed an Internal Medicine residency at Harvard followed by a clinical hematology-oncology fellowship at UCLA and has authored over 100 peer-reviewed publications.